Aprea Therapeutics, Inc.
APRE· Nasdaq
APREAprea Therapeutics, Inc.
Filed Nov 9, 2022 · 10-Q · 40 days after period end · 0001558370-22-017205
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Net Income | -$4.02M | -$9.45M | -$12.32M | -$6.25M |
| EPS Diluted | -$2.32 | -$0.45 | -$0.58 | -$5.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aprea Therapeutics, Inc. · CIK 1781983 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end
